The Centre of Excellence in Cellular Immunotherapy (CoE CIT), located at the Peter MacCallum Cancer Centre, was established as a Cellular Immunotherapy IP Accelerator Platform: to collaboratively identify, develop and deliver globally competitive and commercially viable breakthroughs in CAR-T and other cellular immunotherapies for the treatment of cancer. Co-funded by the Australian Commonwealth, the Peter Mac Foundation and Peter Mac, in partnership with the co-located GMP manufacturing CMO Cell Therapies Pty. Ltd., the CoE CIT partners with Australian academic researchers and small biotech companies to fast-track innovative discovery research into manufactured cell-based therapies delivered to the clinic in the form of pilot proof-of-concept clinical trials. The CoE CIT provides a fully funded Development Program that includes preclinical safety testing, method of manufacture optimisation, tech transfer to Cell Therapies, and running of a Phase I clinical trial. Supported by the broader translational, clinical and manufacturing ecosystem within the Parkville precinct, the CoE CIT Development Program provides a truly unique platform that delivers translational capabilities for novel cellular immunotherapies, with the aim of achieving commercial outcomes to advance Australian-generated IP. In this talk, we will cover the Centre's capabilities, outline the Development Program and provide information on how researchers can apply for this scheme.